SXMDF Stock UPDATES Sirtex Medical Ltd (SXMDF) 18.4900 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sirtex Medical Ltd (SXMDF) 18.4900 $SXMDF

Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Fourth Quarter
Business Wire - Mon Jul 07, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres(R) microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.

Brachytherapy Global Strategic Business Report 2014: Competition Heats Up in the Brachytherapy Market
M2 - Thu Jun 12, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zllh3/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 36 companies including many key and niche players such as: - Best Medical International - Best Vascular - Boston Scientific - COOK Medical - C. R. Bard - Eckert & Ziegler Strahlen & Medizintechnik - Gammex - Nucletron - Oncura - Sirtex Medical - Theragenics - Varian Medical Systems - Xoft Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW - Brachytherapy - A Prelude - The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth - Brachytherapy Provides More Hope for Cancer Patients Compared to EBRT - Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment - Growing Cancer Cases in Developing Countries Bodes Well for the Brachytherapy Market - Recent Technological Advancements Show Promising Future for the Brachytherapy Market 2. MAJOR MARKET DRIVERS, TRENDS & ISSUES 3. RESEARCH & STUDY FINDINGS 4. PROSTATE CANCER A MAJOR BRACHYTHERAPY INDICATION 5. OTHER MAJOR BRACHYTHERAPY INDICATIONS 6. PRODUCT OVERVIEW 7. BRACHYTHERAPY EQUIPMENT 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/7z...chytherapy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Sirtex and Guerbet to Collaborate on Clinical Studies in Primary and Secondary Liver Cancer
CNW Group - Mon Mar 24, 10:42AM CDT
Sirtex Medical Limited (ASX:SRX) and Guerbet S.A. (EPA:GBT) announce today that the two companies will enter into a major clinical studies collaboration in primary and secondary (metastatic) liver cancer. The objective of the collaboration is to examine how Sirtex's SIR-Spheres(®) microspheres and Guerbet's Lipiodol(®) may be combined or sequenced optimally - and further developed - to address the significant unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumours, and a range of other primary and secondary liver cancers.

Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer
PR Newswire - Mon Mar 24, 10:25AM CDT
Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*.

Sirtex Medical Inc. Reports 23.7 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Second Quarter
Business Wire - Mon Jan 13, 9:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that second quarter dose sales of SIR-Spheres(R) microspheres grew 23.7 percent in the Americas region compared to the previous corresponding period for the quarter ending December 31, 2013.

Liver Cancer Global Clinical Trials Review, H2, 2013 Features Players such as Pfizer Inc., Eli Lilly and Company and Novartis AG
M2 - Fri Dec 13, 5:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/btqlz5/liver_cancer) has announced the addition of the "Liver Cancer Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cancer Global Clinical Trials Review, H2, 2013" provides data on the Liver Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cancer. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Companies Mentioned: -AstraZeneca PLC -Bayer AG -Bristol-Myers Squibb Company -Eastern Hepatobiliary Surgery Hospital -Eli Lilly and Company -F. Hoffmann-La Roche Ltd. -FUDAN University -Massachusetts General Hospital -Memorial Sloan Kettering Cancer Center -National Cancer Institute -National Taiwan University Hospital -Novartis AG -Pfizer Inc. -Sanofi -Sirtex Medical Limited -Stanford University -Sun Yat-sen University -The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/bt...ver_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Sirtex Medical Inc. Reports 21 Percent Dose Sales Growth of SIR-Spheres(R) microspheres
Business Wire - Tue Sep 03, 10:44AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced dose sales of SIR-Spheres microspheres grew a solid 21 percent with more than 4,750 doses being supplied in the Americas region for the year ending June 30, 2013.

Sirtex Reports 13.1 per cent Dose Sales Growth in Fourth Quarter
Business Wire - Wed Jul 03, 3:42AM CDT
Sirtex Medical Limited (ASX:SRX) today announced dose sales of its SIR-Spheres(R) microspheres targeted radiation therapy for liver cancer grew 13.1 per cent for the quarter ended 30 June 2013 compared to the previous corresponding period. For Financial Year 2013 dose sales of SIR-Spheres microspheres grew 19 per cent. Despite being off a higher base, the FY2013 result delivers continued strong dose sales growth following the 23 per cent growth in FY2012, 19 per cent growth in FY2011 and 14 per cent growth in FY2010.

Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets
PR Newswire - Thu Jun 20, 5:00AM CDT
Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.

CEO of Sirtex Medical Gilman Wong Selected for Inclusion in The CEO Magazine
PRWeb - Mon May 27, 6:11AM CDT
On a beautiful night in Sydney, the publication that you hold in your hands hosted the 2012 Executive of the Year Awards, recognising Australia's best C-suite leaders. The top accolade for the evening went to Gilman Wong, CEO of Sirtex Medical. Gilman received the award for his tireless work with the global workforce that has brought hope and relief to people with inoperable liver cancer.

Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres(R) Microspheres as First-Line Treatment for Colorectal Liver Metastases
Business Wire - Sat Apr 13, 7:00AM CDT
Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced yesterday the completion of patient recruitment into the group's landmark SIRFLOX randomized controlled trial of SIR-Spheres(R) microspheres for patients with metastatic colorectal cancer. The SIRFLOX study is the world's largest randomized controlled trial in interventional oncology with more than 500 patients enrolled.

Sirtex Medical Inc. Announces Half-Year Dose Sales Report
Business Wire - Mon Mar 04, 8:50AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew more than 35 percent for the first half of the company's fiscal year, compared to the same period last year. Globally the company reported dose sales growth of 30.5 percent in the six months ending Dec. 31, 2012.

Sirtex Medical Inc. Hosts Dinner Symposium at the 2013 American Hepato-Pancreato-Biliary Association's Annual Meeting
Business Wire - Tue Feb 19, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today it will host a dinner symposium during the 2013 American Hepato-Pancreato-Biliary Association's (AHPBA) Annual Meeting. The educational event will take place Thursday, Feb. 21 from 7-8:30 p.m.at the Eden Roc Renaissance in Miami.

Sirtex Medical: Interim report - half-year ended 31 December 2012
Business Wire - Thu Feb 14, 7:00AM CST
--Global dose sales growth of 30.5 per cent

Sirtex Medical Inc. Announces Second Quarter Sales Growth
Business Wire - Tue Jan 15, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew 29 percent for the second quarter of fiscal year 2013 over the same period last year. Globally the company reported dose sales grew 25 percent year-on-year for the second fiscal quarter of 2013 ending Dec. 31, 2012.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

Gamehaus Holdings Inc. Launches Strategic Share Buyback Plan

Updated Category News Views 222

Gamehaus Holdings Inc. Introduces New Share Repurchase Program Gamehaus Holdings Inc. (Nasdaq: GMHS), a leading mobile game publisher focused on technology, has announced a significant move aimed at returning value to its shareholders. The company has authorized a share repurchase program that allows it to buy back up to US$5 million of its Class A ordinary shares. This...

Continue Reading
AMN Healthcare's Upcoming Earnings Call: What to Expect

Updated Category News Views 191

AMN Healthcare's Upcoming Earnings Conference Call AMN Healthcare Services, Inc. (NYSE: AMN) has announced an important conference call planned for Thursday, November 6, 2025, at 5:00 p.m. Eastern Time. This event aims to provide valuable insights into the company’s third quarter financial results and the outlook for the fourth quarter of the same year. Investors and...

Continue Reading
J&T Express Marks Profit Milestone in 2024 with Strong Growth

Updated Category News Views 520

J&T Express Achieves Profit Milestone Amid Impressive Growth J&T Global Express Limited, commonly known as J&T Express, reported remarkable achievements in its recent annual results, highlighting significant milestones in revenue growth and profitability. In a remarkable development, the company made a substantial leap in the logistics sector, marking its first full-year...

Continue Reading
Innovative Smart Walking Stick Enhances Safety for Users

Updated Category News Views 207

Introducing the Artisan Smart Walking Stick In a world where mobility and safety are paramount, innovation plays a crucial role in enhancing the lives of individuals. The Artisan Smart Walking Stick is a groundbreaking invention emerging from dedicated inventors focused on providing greater independence and safety for users like the elderly and visually impaired. The...

Continue Reading
Golden Ocean Group Limited Announces AGM Resolutions and Results

Updated Category News Views 156

Golden Ocean Group Limited 2025 Annual General Meeting Overview Golden Ocean Group Limited, known by the ticker symbols Oslo:GOGL and Nasdaq:GOGL, recently held its Annual General Meeting (AGM), an essential gathering designed to keep shareholders informed and involved in the company's progress and direction. The meeting showcased the financial health of the organization,...

Continue Reading